MaRS Innovation portfolio company completing Phase 1 human clinical trial of drug to prevent dermal scarring
VANCOUVER (February 16, 2016) — Accel-Rx Health Sciences Accelerator (Accel-Rx), a Centre of Excellence for the Commercialization of Research (CECR), and its partner BDC Capital today announced their second joint investment in ScarX Therapeutics, a Canadian biotechnology company commercializing innovative treatments for dermal scarring (fibrosis).
Accel-Rx and BDC Capital, and other investors including MaRS Innovation, have invested a total of $2 million in ScarX. This investment will ...
Applications for next MSc PoP granting round being accepted until February 25, 2016
TORONTO (January 26, 2016) — Nine Ontario-based medical research projects built on great science with potential for significant economic impact are advancing a step closer to market entry thanks to funding from Ontario Centres of Excellence’s Medical Sciences Proof-of-Principle (MSc PoP) program. The projects range from cancer to heart disease to sleep apnea in children.
Applications for the next MSc PoP granting round are open until March 4, 2016. To ...
TORONTO and VANCOUVER, CANADA (January 12, 2016) — A novel drug therapy to reduce the severity and frequency of hypoglycemic (low blood sugar) episodes in people with diabetes is being developed by Zucara Therapeutics Inc.
This new start-up company, created by MaRS Innovation and The Centre for Drug Research and Development (CDRD) is based on decades of diabetes research by renowned University of Toronto (U of T) professor, Dr. Mladen Vranic.
Zucara Therapeutics will attend Does of the Valley in February 2016. The ...
MLA48 leads ConferenceCloud pre-seed round in cooperation with UTEST
TORONTO, CANADA (January 11, 2016) — MLA48, Canada’s first angel investment fund committed to providing a 48-hour turnaround on investment decisions, has announced its third investment in ConferenceCloud, an innovative digital platform that provides a virtual solution for the next generation of hybrid conference events.
TechVibes and BetaKit covered this announcement. The University of Toronto also published a web story on Olivia and John-Alan Simmons and their start-up journey.
Founded in 2014 by siblings Olivia ...
2015 created a flurry of activity for MaRS Innovation and our portfolio. As the holidays begin, here are our picks for the top 10 news stories from MI's portfolio in 2015. We look forward to more exciting developments in 2016.
You may also have noticed we've refreshed our website and re-organized how we communicate about our work and services. We'd love to hear your thoughts: contact Elizabeth Monier-Williams.
Top 10 MI Portfolio Stories for 2015
1. ChipCare Corporation, a University of Toronto start-up company ...
UTEST graduate eQOL has received $350,000 from the Ontario Government to support patients managing their kidney dialysis at home. eQOL's solutions use mobile tablets technology to support patients in managing independent care at home.
The funding, part of an Ontario Centres of Excellence program to support technology used to remotely monitor and care for Ontario patients, was announced December 1, 2015 and covered in Canadian Healthcare Technology.
eQOL has partnered with London Health Sciences Centre, Ontario Telemedicine Network and the Kidney Foundation of Canada ...
TORONTO and SAN DIEGO (December 8, 2015) — Triphase Accelerator Corporation, a private drug development company dedicated to advancing novel compounds through Phase 2 proof-of-concept, today announced that positive results from its ongoing Phase 1 proof-of-concept study evaluating marizomib in patients with relapsed and refractory multiple myeloma will be presented at the 57th Annual Meeting of the American Society of Hematology (ASH).
The company will also present preclinical data on marizomib demonstrating synergistic activity in combination with pomalidomide. Marizomib is a novel ...
"In a project spearheaded by PhD candidate Reza Nosrati, U of T researchers are trying to learn more about the way sperm cells move — something that could benefit those using in vitro fertilization (IVF)," writes Daniel Otis in "Sperm show U of T researchers a new trick: slithering" published in the Toronto Star on November 13, 2015.
MaRS Innovation is working with Professor David Sinton, Nosrati and the university's Innovations and Partnerships Office to commercialize the technology for the human sperm ...
TORONTO and SAN DIEGO (November 19, 2015) -- Triphase Accelerator Corporation, a private drug development company dedicated to advancing novel compounds through Phase 2 proof-of-concept, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for marizomib to treat patients with malignant glioma.
Malignant glioma is an aggressive form of brain cancer for which there is a significant unmet need in current treatments due to the disease's poor prognosis. Triphase is evaluating marizomib, a novel and highly ...
Flybits, a Ryerson University start-up company created in partnership with MaRS Innovation, has been named to Deloitte's Technology Fast 50 Companies to Watch list.
According to TechVibes, "Companies were selected for their technological innovation, entrepreneurship, leadership and growth. Now in its 18th year, Technology Fast 50 celebrated companies with an average four-year growth rate of 1,293%."
You can read TechVibes' coverage of the Deloitte announcement here. The full list, of which 62% are software companies, is posted on Deloitte's website.